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INTRODUCTION: ALZHEIMER’S DISEASE
ØAlzheimer’s disease (AD) is the most common type of dementia among 
the elderly and the most prevalent neurodegenerative disorder.
Ageing population à Prevalence, mortality and economic burden ↑
Ø Current drugs cover symptoms à Need for disease-modifying therapies.
Ø AD is a multifactorial disease, with a complex pathological network [1] 
à Need for multitarget drugs.
PREVIOUS WORK
Previously in the group, a lead rhein-huprine hybrid was
developed [2,3], with a multitarget biological profile.
§ Rhein à 𝜏 antiaggregating activity
§ Huprine Y à AChE inhibition
Molecular modelling studies in BACE-1 [2,4] showed a 
dual binding mode: catalytic pocket (huprine Y) and 
non-described transient secondary pocket (rhein). Figure 1. Rhein-huprine lead.
OBJECTIVE
Virtual screening campaign directed toward
the secondary binding site of BACE-1 à hits







Figure 2. Structure of the identified BACE-1
secondary site virtual screening hits (VSH) and design
of the target compounds (3-8), highlighting the
putative interactions of the VSH moieties.
SYNTHESIS
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Seven structures were selected based on the
virtual screening campaign, and the
corresponding final hybrids containing the VSH
and huprine Y moieties linked through a 9-












Four out of the six VSH-based hybrids
presented weak BACE-1 inhibition,
showing up the difficult ligandability of
this target through small molecules.
However, after in vitro and chronic in vivo
efficacy studies in SAMP8 mice compound
5 emerged as a promising anti-Alzheimer
lead that improves memory and learning
and impacts the natural course of AD-like
pathology at multiple levels.
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IN VIVO EFFICACY STUDIES (5)
1. Behavioral Tests
• NORT à + working memory
• OLT à + spatial memory
2. Positive effects on Amyloid Processing 
Pathway and Tau Pathology
3. ↓ Tau hyperphosphorylation
4. ↓ Oxidative Stress, ↓ Inflammatory 
Markers
5. ↑ Synaptic Plasticity
IN VITRO BIOLOGICAL PROFILING
hBACE-1 















5 2.71 ± 0.2 2.57 ± 0.20 43.0 ± 2.7 49.5 ± 1.6 65.8 ± 1.9 +
1 1.50 ± 0.38 3.60 ± 0.21 620 ± 20 47.9 ± 14.5 29.6 ± 8.5 +





DDPH free radical scavening assay







5 29.2 ± 2.8 39.4 ± 9.4% ns > 100
Table 1. aValues are expressed as mean ± SEM of at least three experiments, each one performed in duplicate;
bMTT assay on neuronal HT-22 cells treated with 1, 5, 10 and 25 µM of the compounds; cZebrafrish embryo
acute toxicity assay, LC50 calculated by adjusting the results of the means of the six tested groups of at least
three experiments per compound, CI95 confidence interval for LC50;; ns not significant.
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